Business, energy, technology, markets and global industry news from Business News Today

prostate cancer

PharmaDeviceNews prostate cancer
Representative image: A pathology specialist reviews PTEN biomarker staining as NeoGenomics launches an FDA-approved companion diagnostic to identify prostate cancer patients who may be eligible for AstraZeneca’s Truqap.
Medical Devices & Diagnostics

How the NeoGenomics PTEN IHC test supports targeted prostate cancer treatment

NeoGenomics launches an FDA-approved PTEN IHC companion diagnostic to identify prostate cancer patients eligible for AstraZeneca’s Truqap.

Read More
Pharma & Biotech

Lupin’s tentative FDA approval for enzalutamide sets up a high-value generic challenge to Xtandi

Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.

Read More
Representative image of clinicians reviewing genomic cancer testing data and medical imaging, reflecting Veracyte’s Prosigna and Decipher ASCO 2026 results and the growing role of precision oncology diagnostics in breast cancer and prostate cancer treatment decisions.
Medical Devices & Diagnostics

Can Veracyte’s Prosigna data change chemotherapy decisions in high-risk breast cancer?

Veracyte’s ASCO data could reshape chemotherapy decisions in breast and prostate cancer. Find out why genomic testing is gaining ground.

Read More
Representative image of a clinician reviewing prostate cancer imaging in a modern nuclear medicine setting, reflecting Convergent Therapeutics’ CONV01-α Phase 2 data and the growing race to develop Actinium-225 radiopharmaceuticals for post-Lu-PSMA metastatic prostate cancer.
Pharma & Biotech

Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?

CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.

Read More
Representative image of an oncology consultation for advanced prostate cancer treatment, as Bayer’s NUBEQA cognitive decline data from the ARACOG trial raises new questions about quality-of-life differences between darolutamide and enzalutamide.
Pharma & Biotech

Could Bayer’s NUBEQA gain a quality-of-life edge after ARACOG cognitive data?

Find out how Bayer’s NUBEQA cognitive data from ARACOG could reshape prostate cancer treatment choices after ASCO 2026.

Read More
Medical Devices & Diagnostics

Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?

Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.

Read More
Pharma & Biotech

Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3

Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.

Read More
Representative image: Actinium Pharmaceuticals’ ATNM-400 update and new Actimab-A and Iomab-ACT patent allowances underscore rising investor and clinical interest in targeted radiotherapy, actinium-225 cancer treatments and next-generation radiopharmaceuticals.
Pharma & Biotech

Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026

Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.

Read More
Representative image of AI-powered digital pathology being used to analyse prostate cancer biopsy slides, reflecting Acupath Laboratories’ integration of the ArteraAI Prostate Test into its diagnostic workflow for localized prostate cancer risk stratification.
Medical Devices & Diagnostics

What Acupath’s ArteraAI Prostate Test rollout reveals about the next phase of precision oncology

Acupath adds ArteraAI Prostate Test to its pathology workflow. Find out what it means for AI prostate cancer risk stratification today.

Read More
Medical Devices & Diagnostics

Veracyte’s ASCO 2026 data could sharpen the commercial case for genomic cancer diagnostics

Veracyte’s ASCO data could sharpen the case for genomic testing in breast and prostate cancer. Read why adoption still faces hard tests.

Read More